Table 2.
Frequency of incident bladder cancer and exposure to diabetes medications, overall and by sex
| Bladder cancer cases/diabetes medications | Prevalent cohort | Incident cohort |
|---|---|---|
| Number of bladder cancer cases | 4433 (0.4%) | 1159 (0.4%) |
| Incidence of bladder cancer (cases/1000 PY) | 1.08 | 1.16 |
| Pioglitazone use (N) | 20.1% (233,450) | 11.9% (38,091) |
| Mean exposure, months (SD) | 21.1 (31.8) | 16.6 (27.7) |
| Rosiglitazone use (N) | 10.4% (120,790) | 4.8% (15,364) |
| Mean exposure, months (SD) | 16.5 (17.6) | 11.2 (14.2) |
| ARB use (N) | 31.6% (367,016) | 28.6% (91,546) |
| Mean exposure, months (SD) | 24.5 (25.5) | 20.8 (22.0) |
| ACE-I use (N) | 58.9% (684,090) | 53.0% (169,648) |
| Mean exposure, months (SD) | 28.1 (37.6) | 22.2 (30.7) |
| Metformin use (N) | 61.1% (709,642) | 61.4% (196,535) |
| Mean exposure, months (SD) | 58.3 (59.7) | 37.5 (42.8) |
| Sulfonylurea use (N) | 51.8% (601,627) | 39.6% (126,756) |
| Mean exposure, months (SD) | 29.1 (23.4) | 22.1 (20.1) |
Data are presented as the number (of enrollees) with the percentage in parenthesis, as the percentage with the number (of enrollees) in parenthesis or as the mean with the SD in parenthesis
PY Person-years, ARB angiotensin II receptor blocker, ACE-I angiotensin converting enzyme inhibitors